Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Slides:

Advertisements

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Advertisements

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 1. Anemia in patients with central diabetes insipidus.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 3. Obese IFN-γ−/− mice develop accelerated NAFLD with fibrosis.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating lymphocytes. Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 1 pDCs infiltrate the skin of SSc patients and spontaneously secrete IFN-α and CXCL4. pDCs infiltrate the skin of SSc patients and spontaneously secrete.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 3 BX795 blocks the synthesis of HSV-1 virions.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Intravenous delivery of reovirus to primary and secondary brain tumors

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 5 Acute loss of mitochondrial content after impact is prevented by inhibition of electron transport or critical redox events. Acute loss of mitochondrial.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 2 In vitro assessment of hESC-RPE cell sheets.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Fig. 4. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. Restriction of TCR antigen.

Fig. 5. Accelerated NASH-driven fibrogenesis in obese IFN-γ−/− mice is characterized by severe eosinophilic inflammation during TGF-β blockade. Accelerated.

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Role of immune and inflammatory cells in lung cancer–associated PH

Fig. 7. NPs accumulate at sites of vascular obstruction.

Fig. 4. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. Analysis of T cell responses.

Fig. 5. pKL cells abrogate the autoimmune response in vitro.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2.

Fig. 4 TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine MSCs. TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV.

Fig. 1 CpG induces the expression of OX40 on CD4 T cells.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 2 Analysis of CLL lymph nodes.

Fig. 1 Effect of preinfection β7Hi CD45RA−CD4+ T cell frequency on HIV acquisition risk in CAPRISA 004 study. Effect of preinfection β7Hi CD45RA−CD4+ T.

PAAND is driven by local inflammasome activation and IL-1β production

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

Fig. 1 CSPG4 is expressed in GBM specimens and GBM-NS and associated with more aggressive disease. CSPG4 is expressed in GBM specimens and GBM-NS and associated.

Evaluation of clinical responses after infusion of CART19 cells

Selection of a 4-1BB-endodomain–based anti-EGFRvIII CAR construct

Fig. 4. Acute lung injury in miR-223−/y mice.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 6 Photoreceptor cell survival in the RCS rat retina after transplantation with hESC-RPE cell sheets. Photoreceptor cell survival in the RCS rat retina.

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 2. Increased CD19 CAR-T cell expansion and persistence after Cy/Flu lymphodepletion. Increased CD19 CAR-T cell expansion and persistence after Cy/Flu.

Fig. 7 Transient immunosuppression (4 weeks) supports long-term graft survival and is associated with progressive decrease in spinal regional inflammatory.

Donor and recipient BAL T cells are phenotypically and functionally memory T cells. Donor and recipient BAL T cells are phenotypically and functionally.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 1 ZIKV RNA in blood and tissues.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 4. Long-term persistence of CTL019 cells and polyfunctionality in patients achieving CR. Long-term persistence of CTL019 cells and polyfunctionality.

Intratumoral lymphoid aggregates are sites of postvaccination T-cell activation and regulation. Intratumoral lymphoid aggregates are sites of postvaccination.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia by David L. Porter, Wei-Ting.

Fig. 3. Association between peak CTL019 expansion and response.

Presentation transcript:

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. (A) T cell infiltration and phenotyping in pre– and post–CART-EGFRvIII infusion specimens from subject 216; pre-infusion specimens are from day −81, whereas post-infusion specimens are from day +13, relative to CART-EGFRvIII infusion at day 0. Top row shows low-power magnification of CD3 immunohistochemical stain, with high-power magnification as inset; ISH specifically for CAR sequences. T cell phenotyping is shown with ISH for IFN-γ and with immunohistochemistry for CD8, granzyme B (GRZMB), and the IL-2 receptor α chain (CD25). Scale bars, 4 mm (low-power graphs) and 200 μm (high-power graphs). (B) In situ assessment of immunosuppressive molecules in the tumor microenvironment is shown before and after CART-EGFRvIII infusion in patient 216, including IDO1, PD-L1, FoxP3, TDO, IL-10, and TGFβ. (C) Summary table with heat map of T cell infiltration, CART-EGFRvIII trafficking, and tumor microenvironment in seven subjects before and after treatment with CART-EGFRvIII. NP, not performed; 0, not detectable. Date indicates day of specimen relative to CART-EGFRvIII infusion, which was designated as day 0. Donald M. O’Rourke et al., Sci Transl Med 2017;9:eaaa0984 Published by AAAS